

Supplement 1

Data collection form

Section 1: Demography, diagnosis, neoadjuvant treatment

Demographic data and previous therapies	
Name/identifier	
Centre	
Country	
Age	
Sex	
Primary tumor site	
For colorectal cancer-exact site of the primary	
For ovarian cancer- exact site (ovaries, FT, peritoneum)	
Timing of PM (synchronous/metachronous)	
Date of diagnosis of the primary	
Date of diagnosis of PM	
TNM stage at diagnosis	
FIGO stage at diagnosis (for ovarian cancer)	
Prior CRS	
Date of prior CRS	
Prior CRS+HIPEC	
Date of prior CRS+HIPEC	
Prior surgery (not CRS)	
Prior surgical score	
Previous chemotherapy	
Number of lines of previous chemotherapy	
Histological and molecular features	
Histological diagnosis	
Tumor grade (high/low)	
Tumor differentiation (well, moderate, poor, undifferentiated)	
Immunohistochemistry, if relevant (positive markers)	
Immunohistochemistry, if relevant (negative markers)	
BRCA (mutated/wt/not evaluated)	
KRAS (mutated/wt/not evaluated)	
BRAF (mutated/wt/not evaluated)	
NRAS (mutated/wt/not evaluated)	
BAP-1 (mutated/wt/not evaluated)	
EGFR (mutated/wt/not evaluated)	
Ki-67 (mention exact value in percentage)	

Any other marker (name)	
Mutation status	
Any other marker (name)	
Mutation status	
Neoadjuvant therapies	
Neoadjuvant chemotherapy	
Intravenous/oral	
Regimen	
Number of cycles	
Date of starting	
Date of completion	
Neoadjuvant PIPAC	
Regimen	
Number of applications	
Date of start	
Date of completion	
Neoadjuvant port directed IP chemotherapy	
Regimen	
Number of cycles	
Date of start	
Date of completion	
Neoadjuvant HIPEC	
Regimen	
Number of cycles	

Section 2 Radiology

Peritoneal MRI	
CT scan with oral and IV contrast	
CT scan with IV contrast	
PET CT scan	
Any other (please specify)	
Radiological PCI	
Region 0	
Morphological description	
Region 1	
Morphological description	
Region 2	
Morphological description	
Region 3	

Morphological description	
Region 4	
Morphological description	
Region 5	
Morphological description	
Region 6	
Morphological description	
Region 7	
Morphological description	
Region 8	
Morphological description	
Region 9	
Morphological description	
Region 10	
Morphological description	
Region 11	
Morphological description	
Region 12	
Morphological description	
Evaluation of response	
RECIST criteria	
Any other(please specify)	
Progressive disease	
Stable disease	
Partial disease	
Complete response	
Nodal disease	
Right pelvic nodes (disease/no disease)	
Max diameter	
Left pelvic nodes (D/ND)	
Max diameter	
Paraaortic nodes (D/ND)	
Max diameter	
Mesorectal nodes (D/ND)	
Max diameter	
Paracolic nodes (D/ND)	
Max diameter	
Small bowel nodes (D/ND)	
Max diameter	
CBD/periportal (D/ND)	
Max diameter	
Left gastric nodes (D/ND)	

Max diameter	
Peripancreatic nodes (D/ND)	
Max diameter	
Supradiaphragmatic nodes (D/ND)	
Max diameter	
Paracardiac (D/ND)	
Max diameter	
Any other-specify (D/ND)	
Max diameter	
Peritoneal nodes (D/ND)	
Max diameter	
Ascites	
Ascites	
Quantity	
Characteristic	
Density (for mucinous ascites)	
Primary tumor site	
Primary tumor site (evaluated/not evaluated)	
Disease- present or absent	
Response in the primary	
Regional nodes	
Radiological T stage	
Radiological N stage	
Radiological M stage	
Previous anastomosis (evaluated/not evaluated)	
Disease- present/absent	
Stoma site- evaluated/not evaluated	
Disease- present/absent	
PORT site- evaluated/not evaluated	
Disease-present/absent	
Previous surgical scar- evaluated/not evaluated	
Disease-present/absent	

Section 3 Surgical and perioperative details

ASA	
ECOG Status	
Date of CRS	
Resection of the primary	

HIPEC	
Open/closed	
Drug regimen	
Duration	
Surgical PCI	
Region 0	
Morphological description	
Region 1	
Morphological description	
Region 2	
Morphological description	
Region 3	
Morphological description	
Region 4	
Morphological description	
Region 5	
Morphological description	
Region 6	
Morphological description	
Region 7	
Morphological description	
Region 8	
Morphological description	
Region 9	
Morphological description	
Region 10	
Morphological description	
Region 11	
Morphological description	
Region 12	
Morphological description	
Perioperative outcomes	
Duration of surgery	
Blood loss	
Post op ventilation (hours)	
ICU stay	
Hospital stay	
Grade 1-2 complications	
90-day grade 3-4 morbidity	
Haemorrhage	
Specify	
Hematological toxicity	

Specify	
Respiratory complications	
Specify	
Sepsis	
Specify	
Neutropenia	
Lowest count	
Cardiac complications	
Specify	
GI complications	
Specify	
Bowel fistula	
Specify	
Bowel perforation	
Specify site	
Renal complication	
Specify	
Nephrological complications	
Specify	
Wound dehiscence	
Site	
Surgical site infection	
Return to ICU	
Duration of stay	
Return to operating room	
Procedure performed/indication	
Radiological intervention	
Specify	
Mortality	
Date of death	
Cause of death	

Section 4 Pathology

No of specimens	
No of blocks	
Pathological PCI	
Region 0	
Morphological description	
Region 1	
Morphological description	
Region 2	
Morphological description	

Region 3	
Morphological description	
Region 4	
Morphological description	
Region 5	
Morphological description	
Region 6	
Morphological description	
Region 7	
Morphological description	
Region 8	
Morphological description	
Region 9	
Morphological description	
Region 10	
Morphological description	
Region 11	
Morphological description	
Region 12	
Morphological description	
Nodal disease	
Right pelvic nodes (dissected/not dissected)	
No of nodes	
No of positive nodes	
Left pelvic nodes (D/ND)	
No of nodes	
No of positive nodes	
Paraaortic nodes (D/ND)	
No of nodes	
No of positive nodes	
Mesorectal nodes (D/ND)	
No of nodes	
No of positive nodes	
Paracolic nodes (D/ND)	
No of nodes	
No of positive nodes	
Small bowel nodes (D/ND)	
No of nodes	
No of positive nodes	
CBD/periportal (D/ND)	
No of nodes	
No of positive nodes	
Left gastric nodes (D/ND)	
No of nodes	

No of positive nodes	
Peripancreatic nodes (D/ND)	
No of nodes	
No of positive nodes	
Supradiaphragmatic nodes (D/ND)	
No of nodes	
No of positive nodes	
Paracardiac (D/ND)	
No of nodes	
No of positive nodes	
Any other-specify (D/ND)	
No of nodes	
No of positive nodes	
Peritoneal nodes (D/ND)	
No of nodes	
No of positive nodes	
Greater omental nodes	
No of nodes	
No of positive nodes	
Lesser omental nodes	
No of nodes	
No of positive nodes	
Total no of nodes	
Total no of positive nodes	
Pathological response to systemic chemotherapy	
Bohm score(for ovarian cancer)	
Response grade	
PRGS	
Response grade	
Lyon-score for colorectal PM	
Overall score	
Fibrosis (%)	
Necrosis (%)	
Colloid response (%)	
Any other score used	
Grade	
Additional comments	
Pathological complete response (y/n)	
Sites of complete response (present/absent)	
Evaluation of the primary tumour	
Disease in the primary	
Maximum tumour diameter	

T-stage	
N-stage	
No of dissected nodes	
No of positive nodes	
Extracapsular spread	
Lymphovascular invasion	
Perineural invasion	
Immunohistochemistry-positive markers	
Immunohistochemistry-negative markers	
Target regions and normal peritoneum	
Disease in normal peritoneum	
Falciform ligament (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Umbilical round ligament (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Greater omentum (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Lesser omentum (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Pancreatic capsule (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Viscera	
Glisson's (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Rectum/rectosigmoid colon (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Right colon (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Gall bladder (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Spleen (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	

Stomach (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Small bowel (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Liver (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Intraparenchymal metastases (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Previous anastomotic site (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Previous stoma site (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
PORT SITE (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	
Previous surgical scar (resected/not resected)	
Max tumour diameter on gross examination (mm)	
Microscopic disease (present/absent)	

Section 5 Adjuvant therapy and follow up

Adjuvant therapy	
Adjuvant therapy planned	
Date of start of adjuvant therapy	
Chemotherapy regimen	
Number of cycles	
Targetted therapy	
Drug	
Number of cycles	
Date of last cycle	
Maintenance therapy	
Drug	
Duration	
Follow-up	
Last follow-up	

Disease status	
Date of diagnosis of recurrence	
Site of recurrence	
Site of metastases	
Treatment for recurrence/metastatic disease	
Date of death	
Cause of death	